Nalpropion Pharmaceuticals, v. Actavis Laboratories FL, Inc., No. 18-1221 (Fed. Cir. Aug. 15, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Actavis Laboratories FL, Inc. (“Actavis”) appeals from the judgment of the U.S. District Court for the District of Delaware that (1) its proposed naltrexo ne hydrochloride and bupropion hydrochloride extended- release tablets , which are the subject of Abbreviated New Drug Application No. 208043 (the “ANDA product”) , would infringe claim 1 of U.S. Patent 7,375,111 (“the ’111 patent”), claims 26 and 31 of U.S. Patent 7,462,626 (“the ’626 patent”), and claim 11 of U.S.